Europe Liver Cancer Diagnostics Market Overview
According to SPER Market Research, the Europe Liver Cancer Diagnostics Market is estimated to reach USD 3.11 billion by 2033 with a CAGR of 6.28%.
Liver cancer diagnostics entail a thorough approach for detecting cancerous cells or tumours in the liver. It begins with a thorough evaluation of the patient's medical history and a physical examination to assess symptoms and risk factors. Ultrasound, CT scans, and MRI offer detailed images of the liver that can be used to identify abnormalities and tumour features. Blood tests are critical in detecting liver cancer and monitoring its course by evaluating indicators such as alpha-fetoprotein (AFP). A biopsy confirms the diagnosis of liver cancer if imaging or blood tests indicate it. Biopsies entail the removal of a tiny sample of liver tissue for microscopic analysis. Different methods of biopsies, such as guided needle or surgical biopsies, assure reliable collection. These diagnostic approaches inform treatment selections and assess the disease's scope.
Exploring the Growth Drivers of the Europe Liver Cancer Diagnostics Industry.
Several main reasons have contributed to the huge rise of the Europe Liver Cancer Diagnostics Market. For first of all, the region's increasing prevalence of liver cancer has increased demand for reliable detection procedures. The increasing prevalence of risk factors such as hepatitis B and C infections, alcohol abuse, and non-alcoholic fatty liver disease (NAFLD) has added to the growing burden of liver cancer. Furthermore, advances in medical imaging technologies have improved the accuracy and efficiency of liver cancer detection. High-resolution imaging modalities, such as ultrasonography, CT scans, and MRI, have enhanced the detection and characterization of liver tumours. These imaging techniques allow for the early detection and exact staging of liver cancer, resulting in improved treatment outcomes.
What challenges does the Europe Liver Cancer Diagnostics Market face?
The Europe Liver Cancer Diagnostics Market has a number of issues that will have an impact on its growth and efficacy. To begin with, the complexity of liver cancer itself provides an obstacle because liver cancer frequently presents with nonspecific symptoms, early identification is challenging. This delay in diagnosis can compromise the efficacy of treatment alternatives and result in inferior patient outcomes. Furthermore, liver cancer is frequently linked with other liver illnesses such as cirrhosis, which can make diagnosis more difficult. The cost of liver cancer tests can be too expensive. Advanced imaging techniques and biomarker tests can be costly, and the financial burden may prevent certain individuals or healthcare systems from using these diagnostic tools.
In what ways has the COVID-19 pandemic affected Europe Liver Cancer Diagnostics Market?
The pandemic of COVID-19 has had a substantial influence on the Europe Liver Diagnostic Market. To begin with, the pandemic has disturbed healthcare systems and resources, diverting attention and resources away from non-COVID-19-related illnesses such as liver cancer diagnosis. Due to increased patient load and prioritization of COVID-19 care, many healthcare facilities have been put under strain, resulting in delays in liver cancer detection and treatment. Furthermore, the deployment of infection control measures and constraints on non-essential healthcare services has resulted in a decrease in liver cancer screening, diagnostic procedures, and follow-up visits. Routine screenings and diagnostic procedures may have been delayed or cancelled, resulting in the delayed discovery of liver cancer and, perhaps, more advanced disease stages at diagnosis.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2019-2033 |
| Base year considered | 2022 |
| Forecast period | 2023-2033 |
| Segments covered | By Test Type, By Cancer Stages, By Cancer Type, By Product, By Technology, By Application, By Gender, By End User, By Distribution Channel
|
| Regions covered | Belgium, France, Germany, Italy, Netherlands, Norway, Russia, Spain, Switzerland, Turkey, U.K., Rest of Europe
|
| Companies Covered | ABK Biomedical Inc., Agilent Technologies Inc., Altogen Biosystems, Diagnostic Biosystems Inc., Diazyme Laboratories Inc., Epigenomics AG, F. Hoffmann-La Roche Ltd, FUJIFILM Corporation, Fujirebio, Hipro Biotechnology Co. Ltd., Illumina Inc., Koninklijke Philips N.V., MOLGEN, QIAGEN, Siemens Healthcare GmbH, Sysmex Corporation, Tebubio, Thermo Fisher Scientific Inc., Others
|
Key Target Audience:
- Hospitals
- Cancer research Centres
- Academic Institutes
- Diagnostic Centres
- Ambulatory Centres
- Others
Europe Liver Cancer Diagnostics Market Segmentation:
1. By Test Type:
- Europe Liver Cancer Diagnostics Market Value Share and Forecast, By Test Type, 2023-2033
- Imaging Test
- Biopsy
- Genomic Test
2. By Cancer Stages:
- Europe Liver Cancer Diagnostics Market Value Share and Forecast, By Cancer Stages, 2023-2033
- Stage 0
- Stage I
- Stage II
- Stage III
- Stage IV
3. By Cancer Type:
- Europe Liver Cancer Diagnostics Market Value Share and Forecast, By Cancer Type, 2023-2033
- Primary Liver Cancer
- Secondary Liver Cancer
4. By Product:
- Europe Liver Cancer Diagnostics Market Value Share and Forecast, By Product, 2023-2033
- Platform-Based Products
- Instrument-Based Products
- Kits And Reagents
- Other Consumables
5. By Region:
- Belgium
- France
- Germany
- Italy
- Netherlands
- Norway
- Russia
- Spain
- Switzerland
- Turkey
- U.K.
- Rest of Europe
Key Topics Covered in the Report:
- Europe Liver Cancer Diagnostics Market Size (FY’2023-FY’2033)
- Overview of Europe Liver Cancer Diagnostics Market
- Segmentation of Europe Liver Cancer Diagnostics Market By Test Type (Imaging Test, Biopsy, Genomic Test, and Others)
- Segmentation of Europe Liver Cancer Diagnostics Market By Cancer Stages (Stage 0, Stage I, Stage II, Stage III, and Stage IV)
- Segmentation of Europe Liver Cancer Diagnostics Market By Cancer Types (Primary Liver Cancer and Secondary Liver Cancer)
- Segmentation of Europe Liver Cancer Diagnostics Market By Product (Platform-Based Products, Instrument Based Products, Kits and Reagents, and Other Consumables)
- Segmentation of Europe Liver Cancer Diagnostics Market By Technology (Fluorescent In Situ Hybridization, Next Generation Sequencing, Fluorimmunoassay, Comparative Genomic Hybridization, Immunohistochemical, and Others)
- Segmentation of Europe Liver Cancer Diagnostics Market By Application (Screening, Diagnostic and Predictive, Prognostic, and Research)
- Segmentation of Europe Liver Cancer Diagnostics Market By Gender (Female, Male)
- Segmentation of Europe Liver Cancer Diagnostics Market By End User (Hospitals, Diagnostic Centers, Cancer Research Centers, Academic Institutes, Ambulatory Surgical Centers, and Others)
- Segmentation of Europe Liver Cancer Diagnostics Market By Distribution Channel (Direct Tender, Retail Sales, and Others)
- Statistical Snap of Europe Liver Cancer Diagnostics Market
- Growth Analysis of Europe Liver Cancer Diagnostics Market
- Problems and Challenges in Europe Liver Cancer Diagnostics Market
- Competitive Landscape in the Europe Liver Cancer Diagnostics Market
- Impact of COVID-19 and Demonetization on Europe Liver Cancer Diagnostics Market
- Details on Recent Investment in Europe Liver Cancer Diagnostics Market
- Competitive Analysis of Europe Liver Cancer Diagnostics Market
- Key Players in the Europe Liver Cancer Diagnostics Market
- SWOT Analysis of Europe Liver Cancer Diagnostics Market
- Europe Liver Cancer Diagnostics Market Future Outlook and Projections (FY’2023-FY’2033)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPER’s internal database
2.1.4. Premium insight from KOL’s
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
4.2. COVID-19 Impacts of the Europe Liver Cancer Diagnostics Market
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTER’s Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Europe Liver Cancer Diagnostics Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Europe Liver Cancer Diagnostics Market
7. Europe Liver Cancer Diagnostics Market, By Test Type (USD Million)
7.1. Europe Liver Cancer Diagnostics Market Value Share and Forecast, By Test Type, 2023-2033
7.2. Imaging Test
7.3. Biopsy
7.4. Genomic Test
7.5. Others
8. Europe Liver Cancer Diagnostics Market, By Cancer Stages (USD Million)
8.1. Europe Liver Cancer Diagnostics Market Value Share and Forecast, By Cancer Stages, 2023-2033
8.2. Stage 0
8.3. Stage I
8.4. Stage II
8.5. Stage III
8.6. Stage IV
9. Europe Liver Cancer Diagnostics Market, By Cancer Type (USD Million)
9.1. Europe Liver Cancer Diagnostics Market Value Share and Forecast, By Cancer Type, 2023-2033
9.2. Primary Liver Cancer
9.3. Secondary Liver Cancer
10. Europe Liver Cancer Diagnostics Market, By Product (USD Million)
10.1. Europe Liver Cancer Diagnostics Market Value Share and Forecast, By Product, 2023-2033
10.2. Platform-Based Products
10.3. Instrument-Based Products
10.4. Kits And Reagents
10.5. Other Consumables
11. Europe Liver Cancer Diagnostics Market, By Technology (USD Million)
11.1. Europe Liver Cancer Diagnostics Market Value Share and Forecast, By Technology, 2023-2033
11.2. Fluorescent In Situ Hybridization
11.3. Next Generation Sequencing
11.4. Fluoroimmunoassay
11.5. Comparative Genomic Hybridization
11.6. Immunohistochemical
11.7. Others
12. Europe Liver Cancer Diagnostics Market, By Application (USD Million)
12.1. Europe Liver Cancer Diagnostics Market Value Share and Forecast, By Application, 2023-2033
12.2. Screening
12.3. Diagnostic And Predictive
12.4. Prognostic
12.5. Research
13. Europe Liver Cancer Diagnostics Market, By Gender (USD Million)
13.1. Europe Liver Cancer Diagnostics Market Value Share and Forecast, By Gender, 2023-2033
13.2. Female
13.3. Male
14. Europe Liver Cancer Diagnostics Market, By End User (USD Million)
14.1. Europe Liver Cancer Diagnostics Market Value Share and Forecast, By End User, 2023-2033
14.2. Hospitals
14.3. Cancer Research Centers
14.4. Academic Institutes
14.5. Diagnostic Centers
14.6. Ambulatory Surgical Centers
14.7. Others
15. Europe Liver Cancer Diagnostics Market, By Distribution Channel (USD Million)
15.1. Europe Liver Cancer Diagnostics Market Value Share and Forecast, By Distribution Channel, 2023-2033
15.2. Direct Tenders
15.3. Retail Sales
15.4. Others
16. Europe Liver Cancer Diagnostics Market Forecast, 2019-2033 (USD Million)
16.1. Europe Liver Cancer Diagnostics Market Size and Market Share
17. Europe Liver Cancer Diagnostics Market, By Test Type, 2019-2033 (USD Million)
17.1. Europe Liver Cancer Diagnostics Market Size and Market Share By Test Type (2019-2026)
17.2. Europe Liver Cancer Diagnostics Market Size and Market Share By Test Type (2027-2033)
18. Europe Liver Cancer Diagnostics Market, By Cancer Stages, 2019-2033 (USD Million)
18.1. Europe Liver Cancer Diagnostics Market Size and Market Share By Cancer Stages (2019-2026)
18.2. Europe Liver Cancer Diagnostics Market Size and Market Share By Cancer Stages (2027-2033)
19. Europe Liver Cancer Diagnostics Market, By Cancer Type, 2019-2033 (USD Million)
19.1. Europe Liver Cancer Diagnostics Market Size and Market Share By Cancer Type (2019-2026)
19.2. Europe Liver Cancer Diagnostics Market Size and Market Share By Cancer Type (2027-2033)
20. Europe Liver Cancer Diagnostics Market, By Product, 2019-2033 (USD Million)
20.1. Europe Liver Cancer Diagnostics Market Size and Market Share By Product (2019-2026)
20.2. Europe Liver Cancer Diagnostics Market Size and Market Share By Product (2027-2033)
21. Europe Liver Cancer Diagnostics Market, By Technology, 2019-2033 (USD Million)
21.1. Europe Liver Cancer Diagnostics Market Size and Market Share By Technology (2019-2026)
21.2. Europe Liver Cancer Diagnostics Market Size and Market Share By Technology (2027-2033)
22. Europe Liver Cancer Diagnostics Market, By Application, 2019-2033 (USD Million)
22.1. Europe Liver Cancer Diagnostics Market Size and Market Share By Application (2019-2026)
22.2. Europe Liver Cancer Diagnostics Market Size and Market Share By Application (2027-2033)
23. Europe Liver Cancer Diagnostics Market, By Gender, 2019-2033 (USD Million)
23.1. Europe Liver Cancer Diagnostics Market Size and Market Share By Gender (2019-2026)
23.2. Europe Liver Cancer Diagnostics Market Size and Market Share By Gender (2027-2033)
24. Europe Liver Cancer Diagnostics Market, By End User, 2019-2033 (USD Million)
24.1. Europe Liver Cancer Diagnostics Market Size and Market Share By End User (2019-2026)
24.2. Europe Liver Cancer Diagnostics Market Size and Market Share By End User (2027-2033)
25. Europe Liver Cancer Diagnostics Market, By Distribution Channel, 2019-2033 (USD Million)
25.1. Europe Liver Cancer Diagnostics Market Size and Market Share By Distribution Channel (2019-2026)
25.2. Europe Liver Cancer Diagnostics Market Size and Market Share By Distribution Channel (2027-2033)
26. Europe Liver Cancer Diagnostics Market, By Region, 2019-2033 (USD Million)
26.1. Europe Liver Cancer Diagnostics Market Size and Market Share By Region (2019-2026)
26.2. Europe Liver Cancer Diagnostics Market Size and Market Share By Region (2027-2033)
26.3. Belgium
26.4. France
26.5. Germany
26.6. Italy
26.7. Netherlands
26.8. Norway
26.9. Russia
26.10. Spain
26.11. Switzerland
26.12. Turkey
26.13. U.K.
26.14. Rest of Europe
27. Company Profile
27.1. ABK Biomedical Inc.
27.1.1. Company details
27.1.2. Financial outlook
27.1.3. Product summary
27.1.4. Recent developments
27.2. Agilent Technologies Inc.
27.2.1. Company details
27.2.2. Financial outlook
27.2.3. Product summary
27.2.4. Recent developments
27.3. Altogen Biosystems
27.3.1. Company details
27.3.2. Financial outlook
27.3.3. Product summary
27.3.4. Recent developments
27.4. Diagnostic Biosystems Inc.
27.4.1. Company details
27.4.2. Financial outlook
27.4.3. Product summary
27.4.4. Recent developments
27.5. Diazyme Laboratories Inc.
27.5.1. Company details
27.5.2. Financial outlook
27.5.3. Product summary
27.5.4. Recent developments
27.6. Epigenomics AG
27.6.1. Company details
27.6.2. Financial outlook
27.6.3. Product summary
27.6.4. Recent developments
27.7. F. Hoffmann-La Roche Ltd
27.7.1. Company details
27.7.2. Financial outlook
27.7.3. Product summary
27.7.4. Recent developments
27.8. FUJIFILM Corporation
27.8.1. Company details
27.8.2. Financial outlook
27.8.3. Product summary
27.8.4. Recent developments
27.9. Fujirebio
27.9.1. Company details
27.9.2. Financial outlook
27.9.3. Product summary
27.9.4. Recent developments
27.10. Hipro Biotechnology Co. Ltd.
27.10.1. Company details
27.10.2. Financial outlook
27.10.3. Product summary
27.10.4. Recent developments
27.11. Illumina Inc.
27.11.1. Company details
27.11.2. Financial outlook
27.11.3. Product summary
27.11.4. Recent developments
27.12. Koninklijke Philips N.V.
27.12.1. Company details
27.12.2. Financial outlook
27.12.3. Product summary
27.12.4. Recent developments
27.13. MOLGEN
27.13.1. Company details
27.13.2. Financial outlook
27.13.3. Product summary
27.13.4. Recent developments
27.14. QIAGEN
27.14.1. Company details
27.14.2. Financial outlook
27.14.3. Product summary
27.14.4. Recent developments
27.15. Siemens Healthcare GmbH
27.15.1. Company details
27.15.2. Financial outlook
27.15.3. Product summary
27.15.4. Recent developments
27.16. Sysmex Corporation
27.16.1. Company details
27.16.2. Financial outlook
27.16.3. Product summary
27.16.4. Recent developments
27.17. Tebubio
27.17.1. Company details
27.17.2. Financial outlook
27.17.3. Product summary
27.17.4. Recent developments
27.18. Thermo Fisher Scientific Inc.
27.18.1. Company details
27.18.2. Financial outlook
27.18.3. Product summary
27.18.4. Recent developments
27.19. Others
28. List of Abbreviations
29. Reference Links
30. Conclusion
31. Research Scope